Incidence rates of dysvascular lower extremity amputation changes in Northern Netherlands: A comparison of three cohorts of 1991-1992, 2003-2004 and 2012-2013

Behrouz Fard1,2*, Pieter U. Dijkstra1,3, Roy E. Stewart4, Jan H. B. Geertzen1

1 Department of Rehabilitation Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, 2 Roessingh Center for Rehabilitation, Enschede, the Netherlands, 3 Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, 4 Department of Public Health, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

* Current address: University Medical Center Groningen, Department of Rehabilitation Medicine, RB Groningen, the Netherlands.

Abstract

Objective

To analyze the incidence rates of dysvascular major lower extremity amputations (LEA) in Northern Netherlands in 2012−2013 compared to previous cohorts in 1991−1992 and 2003−2004.

Design

Retrospective cohort study.

Participants

Adults (N = 343) with first ever dysvascular LEA at ankle disarticulation or more proximal levels. The median age (interquartile range) was 74.2 years (64.5–81.9), 64% were male and 55% had been diagnosed with diabetes mellitus (DM).

Main outcome measures

Crude and age-standardized incidence rates of major LEA per 100.000 person-years.

Results

Crude incidence rate (IR) of first ever major LEA in 2012−2013 was 9.9 per 100.000 person-years, while the age-standardized IR was 7.7 per 100.000 person-years. A Poisson regression analysis showed that amputation rates among men were 2.3 times higher compared to women (95%CI 1.9–2.6), while in 2012−2013 the population aged >63 years had decreased amputation rates compared to 1991−1992. In the DM population the crude IR decreased
from 142.6 per 100,000 person-years in 2003–2004 to 89.2 per 100,000 person-years in 2012–2013 (p<0.001).

Conclusions
In 2012–2013 a decrease in age-standardized IR for the general population and a decrease in crude IR for the DM population were observed compared to cohorts from the previous two decades, despite considerable shifts in the age distribution of the Dutch population towards more elderly people and increased prevalence of DM. These findings might suggest that improved treatment of patients at risk of dysvascular amputations is associated with reduced incidence rates of major LEA at the population level.

Introduction
In the past four decades over 90% of major lower extremity amputations (LEA) in the United States and Western European countries were related to peripheral arterial disease (PAD) and diabetes mellitus (DM)[1,2]. An estimated 6% percent of LEA was due to trauma, with the remaining proportion being related to a collection of causes such as cancer and congenital deficiencies[1]. Incidence rates for major LEA show considerable regional variation, as illustrated by a systematic review in 2011[3] in which the incidences were reported to range 3.6 to 69.4 per 100,000 person-years[3]. This variation reflects influence of regional factors such as the quality of health care services and demographic characteristics. However, differences in research methodology (e.g., definition of amputation levels) may also contribute to the variation of the reported incidences[4]. Recent studies report decreasing incidence rates of major LEA in Western European countries such as Germany[5], Spain[6], the United Kingdom[7], and Italy[8], while unchanged rates are reported in Hungary[9] and Ireland[10].

About 42 to 56% of major LEA occur among patients with DM[7,8,11], with the relative risk of major LEA for diabetic and non-diabetic populations ranging from 5.1 to 31.5[4,12,13]. In the past four decades extensive efforts have been made to improve the treatment of DM in regards to glycemic control and prevention of different types of complications[14]. For pediatric care in particular, prevention and treatment of foot ulcers have improved for DM patients[12,15]. Also, considerable advances have been made in the management of PAD: routine use of vascular ultrasonography, improved techniques for percutaneous angioplasty and extensive arterial bypass grafting[16–18].

Life expectancy in Western European countries has increased consistently[19], contributing to a relatively more elderly population and, subsequently, more years of exposure to DM and PAD. Considering these changes, an updated report of the regional incidence rates of major LEA in the Netherlands is expected to provide useful information for health care professionals and to facilitate international comparison. Although a previous study[20] reported unchanged incidence rates between 1991–1992 and 2003–2004 in the Northern region of the Netherlands, we hypothesize that changes in the age distribution in the regional population should be taken into account in analyzing the long term changes of incidence rates. To our knowledge this study is unique, in that major LEA incidences for a region were analyzed in detail, using data at the patient level, for a time frame spanning more than two decades. The aim of the study was to report the incidence rate of first ever dysvascular major LEA in 2012–2013 compared to rates of previous cohorts in 1991–1992[21] and 2003–2004[20]. We expected to find a modest decrease in amputation rates, in line with the reported trends in the literature.
Methods

Data from cohorts 1991–1992, 2003–2004, and 2012–2013 were analyzed, where the cohorts 1991–1992 and 2003–2004 were available to our department. Twelve hospitals -comprising one academic hospital and eleven hospitals with operational endocrinology and surgery departments- in the Northern three provinces of the Netherlands (i.e., Groningen, Friesland and Drenthe) participated in the current study and the previous cohorts. Due to an absence of a nationwide medical registry in the Netherlands, medical records of amputation patients were accessed directly. The University Medical Ethical Committee was consulted and approval was obtained prior to data collection (M15.176087). Additionally, approval in each of the participating hospitals was provided by the Board of Directors or the local Medical Ethical Committees.

Definitions and participants

International Organization for Standardization (ISO)[22] descriptors were used for the terminology of type and level of amputations. Major LEA was defined as any amputation at ankle disarticulation or more proximal level. All major LEA performed from January 1, 2012 through December 31, 2013 were included. Data collection at the hospitals was performed from January 1, 2015 through April 1, 2017. Dysvascular amputation was defined as any major LEA among patients with a recorded medical history of either or both DM and PAD at the time of or prior to the first major LEA according to hospital records or archived documents of the general practitioner. Additional details pertaining to the search strategy and inclusion are provided in the supplemental information S1 Table. For all three cohorts, patients who had undergone major LEA before the study period were excluded. For patients who had undergone multiple amputations during the study periods in the same limb (i.e., reamputation), the most proximal level of amputation was counted once. Patients who had both limbs amputated were counted once as a bilateral amputation. These measures were applied in order to avoid overestimating the incidence rate at the patient level (i.e., by adding up multiple amputations performed on the same patient) and double counting of patients in multiple cohorts. Patients with major LEA due to trauma, cancer, Complex Regional Pain Syndrome type-I, complication of orthopedic surgery, fulminant infection in otherwise healthy adults and congenital deficiencies were excluded. Population data of the adherence area of the hospitals involved were obtained through the open source database of the Dutch Central Bureau for Statistics (CBS) [23] from January 1, 1991 through January 1, 2013, with subpopulations specified by province of residence, sex and 5-years age groups.

Statistical procedures

Due to changes of age distribution in the population between 1991 and 2013, both crude incidence rates (IR) and age-standardized IR were calculated per 100.000 person-years. The crude IR was calculated for the overall population and additionally by sex and age categories, using the corresponding subpopulation data for the denominators. The overall age-standardized IR and by sex were calculated following the direct method[24,25] using the 1991–1992 regional subpopulations as reference. The age distribution of the study population was observed to be left skewed, therefore median ages were presented. Accordingly, differences in median age by sex and DM status were analyzed using the Mann-Whitney U test and the trend of changing median age between 1991 and 2013 were analyzed using the Jonkheere-Terpstra test[26]. For calculating 95% confidence intervals (95%CI) for crude IR and age-standardized IR, a Poisson distribution was assumed. For the main analysis of changes in amputation rates in the general population, a Poisson regression analysis was performed with the three cohorts, sex and age as
predictor variables and the corresponding subpopulations as the off-set variable. Interaction terms between predictor variables were explored. Diabetes status was unavailable for the 1991–1992 cohort, because of which we were unable to analyze changes of LEA incidence in the DM population through a Poisson regression. Incidence rates for the DM population could be only calculated for the 2003–2004 and 2012–2013 cohorts. Crude IR among DM patients and rate ratio’s (RR) were calculated, in which the DM population was estimated through DM prevalence rates by sex and age groups[23]. Changes in crude IR for the DM populations were analyzed using $\chi^2$ tests and by calculating 95% CI for the estimates. For all analyses statistical significance was set at $\alpha = 0.05$. Microsoft Excel 2010, IBM SPSS Statistics 20 and OpenEpi 3.01 were used for the analyses.

**Results**

In 2012 and 2013 a total of 382 patients underwent dysvascular major LEA, 39 patients were excluded due to major LEA prior to the study period. In 2012–2013 64% of the amputation patients were male and 55% were diagnosed with DM (Table 1). The median age of patients at the time of first major LEA between 1991–1992 and 2012–2013 decreased by 2.3 years ($p = 0.019$). In the 2012–2013 cohort the median age of men was 4.2 years lower than that of women ($p = 0.028$) and the median age of DM patients was 2.4 years lower than that of non-DM patients ($p = 0.015$).

**Major LEA in the general population**

Crude IR of major LEA in 2012–2013 was 9.9 per 100,000 person-years, whereas in 1991–1992 and 2003–2004, crude IR was 8.9 and 8.8 per 100,000 person-years respectively (Table 2). Fig 1 is presented in order to illustrate the effect of increased age on incidence rates, as in all three cohorts higher crude IR were observed for the populations aged $\geq45$, $\geq55$, $\geq65$ and $\geq75$

### Table 1. Characteristics of patients undergoing first major LEA in the three historic cohorts.

|                      | 1991–1992 n = 285 | 2003–2004 n = 299 | 2012–2013 n = 343 | P value† |
|----------------------|------------------|------------------|------------------|----------|
| **Level of amputation** |                  |                  |                  |          |
| Transtibial          | 137 (48)         | 146 (49)         | 151 (44)         |          |
| Knee disarticulation | 27 (10)          | 27 (9)           | 20 (6)           |          |
| Transfemoral         | 103 (36)         | 100 (34)         | 147 (43)         |          |
| Bilateral            | 18 (6)           | 25 (9)           | 25 (7)           |          |
| Male                 | 168 (59)         | 180 (60)         | 220 (64)         |          |
| Diabetes*            | -                | 150 (50)         | 190 (55)         |          |
| **Age at amputation, y** |                  |                  |                  |          |
| All                  | 76.5 (68.6–82.7) | 75.5 (66.5–82.6) | 74.2 (64.5–81.9) | 0.019    |
| Men                  | 73.8 (66.9–80.8) | 72.0 (65.0–80.4) | 72.7 (64.3–80.0)‡ | 0.248    |
| Women                | 78.9 (72.7–84.2) | 79.9 (72.0–84.5) | 76.9 (66.2–84.2)‡ | 0.079    |
| DM                   | -                | 75.5 (66.4–81.0) | 72.8 (62.5–80.4)§ |          |
| Non-DM               | -                | 75.7 (67.2–84.1) | 75.2 (67.5–83.9)§ |          |

NOTE. Values are numbers (%), except for age for which median (interquartile range) is provided.

* Diabetes status not available for the 1991–1992 cohort.
† Jonkheer-Terpstra test difference in median age 1991–1992 through 2012–2013.
‡ Mann-Whitney U test difference in median age of men vs women in 2012–2013, $p = 0.028$.
§ Mann-Whitney U test difference in median age of DM vs non-DM patients in 2012–2013, $p = 0.015$.

https://doi.org/10.1371/journal.pone.0204623.t001
years. With the 1991–1992 population as reference, the age-standardized IR of major LEA in 2012–2013 was 7.7 per 100,000 person-years overall, 9.4 per 100,000 person-years among men and 5.7 per 100,000 person-years among women (Table 2). The Poisson regression analysis (Table 3) provided an adequate model fit with no clear over or under dispersion. The

![Fig 1. Crude incidence rate of major LEA for the three historic cohorts, by age categories. Error bars are 95% CI.](https://doi.org/10.1371/journal.pone.0204623.g001)
amputation rates among men were 2.3 times (95%CI 1.9–2.6) higher compared to women, there were no interaction effects for sex between the cohorts and ages. A significant interaction effect was found between age and the three cohorts (p < 0.001). Compared to 2012–2013 in 1991–1992 each one year increase in age was associated with 1.5% increase in amputation rate (RR 1.015; 95%CI 1.004–1.026) and in 2003–2004 each one year increase in age was associated with 1.3% increase amputation rate (RR 1.013; 95%CI 1.002–1.023). Applying the Poisson regression equation in S2 Table provides us with RR between the cohorts for a certain age. For example, applied to the data as presented in Table 3: in 2012–2013 for a 75 year old person the RR of major LEA was 0.84 compared to 1991–1992. Whereas, for a 45 year old person in 2012–2013 the RR was 1.31 compared to 1991–1992. For 2012–2013 the tilting point of RR deviating from 1.0 when compared to 1991–1992 was at 63 years and when compared to 2003–2004 at 70 years.

**Major LEA in the DM population**

Crude IR of major LEA in the 2012–2013 DM population was 89.2 per 100.000 person-years (Table 4), which was a decrease compared to the 2003–2004 rate of 142.6 per 100,000 person-years (χ²(1) = 18.8, p < 0.001). Among male DM patients crude IR decreased from 164.0 to 115.1 per 100,000 person-years (χ²(1) = 6.3, p = 0.012) and from 119.0 to 61.8 per 100,000 person-years (χ²(1) = 14.5, p < 0.001) among female DM patients. Rate ratio of major LEA between DM patients in the DM population and non-DM patients in the general population in 2012–2013 was 18.8 (95%CI 15.2–23.2) for all ages and 8.4 (95%CI 6.9–10.5) in the population aged ≥45 years, with similar rates for men and women: 8.6 (95%CI 6.6–11.3) and 7.9 (95%CI 5.5–11.3) respectively (Table 4).

**Discussion**

Comparing the incidence of major LEA in 2012–2013 with the 1991–1992 cohort, an increase was observed in terms of crude IR and absolute numbers of patients undergoing first ever major LEA. However, the age distribution in the Dutch population shifted considerably towards more elderly people[27]. Compared to 1991 there were 44% more people aged ≥45 years and 39% more people aged ≥75 years in 2013[23]. Considering that the prevalence of PAD and DM also increased in the 20 year time span[28,29], it is reassuring that compared to 1991–1992 and 2003–2004 decreased amputation rates were observed in 2012–2013 for the

### Table 3. Poisson regression model comparing major LEA rates by period, sex and age.

|                | B    | SE  | P value | RR (95% CI)‡ |
|----------------|------|-----|---------|--------------|
| Constant       | -14.48 | 0.28 | <0.001  |              |
| Period†        |      |     |         |              |
| 1991–1992      | -0.93 | 0.42 | 0.025   | 0.394 (0.175–0.888) |
| 2003–2004      | -0.87 | 0.41 | 0.033   | 0.420 (0.189–0.931) |
| Sex (male)     | 0.82  | 0.07 | <0.001  | 2.276 (1.991–2.601) |
| Age†           | 0.08  | 0.01 | <0.001  | 1.084 (1.076–1.092) |
| Age × 1991–1992| 0.02  | 0.01 | 0.007   | 1.015 (1.004–1.026) |
| Age × 2003–2004| 0.01  | 0.01 | 0.021   | 1.013 (1.002–1.023) |

NOTE. Pearson X² (113) = 131.4, p < 0.001.
† Reference category is 2012–2013.
‡ Rate Ratio is calculated by e^B (Wald 95% CI).

https://doi.org/10.1371/journal.pone.0204623.t003
populations aged >63 and >70 years respectively. Following the 1989 St. Vincent Declaration which set up goals to improve the treatment of DM and reduce subsequent complications, considerable efforts were made in the Netherlands for the goals to be achieved in the next decade. The observed decreased incidence of major LEA among patients with DM, PAD or both diseases may be attributable to improvements of glycemic control[30], implementation of intensive multidisciplinary podotiatric care[12,15,31] and improved techniques in vascular surgery[32,33].

In terms of crude IR, age-standardized IR and RR, higher amputation rates were found among men compared to women, whereas women were older at the time of first major amputation in 2012–2013. These observations are similar to those in several other recent studies[8,34–36]. A clinical impression has been that dysvascular amputation patients are older at the time of first major LEA compared to previous two decades. However, in this study amputation patients in the most recent cohort were not older at the time of first major LEA compared to the previous cohorts. The decline of crude IR in the DM population is also reassuring, when we take into account that between 1999 and 2014 the prevalence of DM in the Netherlands had more than doubled[29], in which only 50% of this increase was attributable to the age distribution of the population. As expected, the crude IR in the DM populations were considerably higher compared to that of the general population. DM patients aged 0–40 years in our study were underrepresented in terms of absolute numbers compared to the all ages population. Therefore, we argue that we may only draw conclusions for patients aged ≥45, regarding the rate ratios of major LEA among DM versus non-DM populations.

Comparing incidence rates between regions is challenging due to differences in research methodology such as defining amputation levels, data being acquired at patient or aggregated levels and calculating rates for specific subpopulations (i.e., total, DM and non-DM populations)3,4. Therefore, our study focused on replicating previous studies in our region in order to more precisely compare the incidence rates and changes over time. To our knowledge, this is one of the few studies in which the data were extracted through patients’ records directly. To put the numbers in an international perspective, the decrease of major LEA incidence our study is similar to several recent studies[5,9,34,37]. Decreased major LEA incidence rates in the overall population were reported: from 23.3 to 16.0 per 100.000 person-years in Germany[5], from 23 to 12 per 100.000 person-years in the United States[37], from 14 to 9 per 100.000

Table 4. Crude incidence rates of first ever major LEA for the DM population.

|                          | Crude IR (95% CI) | P value† | RR (95% CI)† |
|--------------------------|------------------|---------|-------------|
|                          | 2003–2004        | 2012–2013 |
| All ages                 | 142.6 (120.7–167.3) | 89.2 (76.9–102.8) | <0.001 | 18.8 (15.2–23.2) |
| Age ≥45                  | 147.3 (124.6–173.0) | 92.1 (79.3–106.4) | <0.001 | 8.4 (6.9–10.5) |
| Men and women            |                  |         |             |
| All ages                 | 164.0 (130.6–203.3) | 115.1 (95.9–137.0) | 0.012 | 19.6 (15.0–25.6) |
| Age ≥45                  | 175.5 (139.6–217.8) | 119.3 (99.1–142.4) | 0.007 | 8.6 (6.6–11.3) |
| Men                      |                  |         |             |
| All ages                 | 119.0 (92.2–151.1) | 61.8 (47.6–78.9) | <0.001 | 16.9 (11.9–24.2) |
| Age ≥45                  | 122.5 (94.9–155.6) | 64.1 (49.3–82.1) | <0.001 | 7.9 (5.5–11.3) |

NOTE. Values per 100.000 person-years.
†χ2 test of crude IR 2003–2004 vs 2012–2013, df = 1.
† Rate Ratio of crude IR for DM vs non-DM populations.

https://doi.org/10.1371/journal.pone.0204623.t004
person-years in Australia[38], whereas unchanged rates of 42.3 per 100,000 person-years were reported in Hungary[9]. Similar to our findings for the DM populations, recent studies reported decreased major LEA incidences: in Italy from 109 to 83 per 100,000 person-years[8], in Scotland from 187 to 111 per 100,000 person-years[39], in Finland from 94.4 to 48.3 per 100,000 person-years[36], whereas in Ireland[10] and the United Kingdom[35] unchanged incidence rates were reported, respectively 47 and 102 per 100,000 person-years. Although the definitions of level of amputation in the aforementioned studies are in line with ours, only two studies[36,39] accounted for multiple amputations per patient (i.e., bilateral and reamputation) in the same manner as we did. Also, except for the Finnish researchers[36], none of the aforementioned studies applied our exclusion of patients with major LEA prior to the study periods. These factors may have contributed to systematically higher incidence rates in other studies. We argue that incidence rates should provide information about the number of patients being confronted with a major LEA for the first time. Because, when multiple amputations among the same patients are added up in IR calculation, any change of IR over time would be problematic to interpret. That is, readers may not be able to distinguish whether the rate of patients who have undergone amputation has changed, or the number of amputations being performed among a subset of high risk patients.

Limitations
Data were collected only in the Northern three provinces of the Netherlands. The total population of this region was approximately 1.7 million people in 2013, which was 10.2% of the total Dutch population[23]. Although the distribution of age and sex in our region is similar to that of the Netherlands in general, we were unable to assess whether the health status was representative to the general population. Therefore, generalizability of the findings to the overall Dutch population may be somewhat limited. Our study design focused on major LEA as an outcome. In assessing amputation rates, it is important to distinguish total, minor and major LEA incidences[4]. Although some contradictory findings have been reported[4], several studies that report decreasing major LEA incidences also report increasing minor LEA rates[5,8,38]. A possible explanation is that more often than in the past, minor amputations are performed on patients at risk of limb amputation in order to prevent complication to major amputation. Lacking any data on minor LEA, we have no means of assessing whether our population followed the same trend.

The use of actual registry data for the denominators in the DM population is preferable to estimation using prevalence rates[35,39,40]. Although recent research in the Netherlands has shown that estimated prevalence rates are similar to actual numbers[41], the incidence rates for the DM population in our study may be less precise due to relatively larger standard error for the younger age groups. Because the dataset for 1991–1992 did not contain separate variables for the presence of DM and PAD for each patient, we were unable to calculate IR for DM and non-DM populations for the 1991–1992 or take DM status into account in the main analysis of the IR change over time in the Poisson regression model. Crude incidence rates for the DM population and non-DM populations for the 2002–2004 and 2012–2013 cohorts are provided as supplemental data S3 Table. In line with a recent systematic review[4] we recommend that future research should preferably provide analysis of crude and age-standardized IR for the total, DM and non-DM populations.

Clinical implication
Lower extremity amputations are associated with high mortality rates[42–44], have high costs in terms of socio-economic burden[43] and may cause considerable disability in the lives of
patients confronted with the loss of a limb[45–47]. Though any amputation is an undesired outcome for patients, we argue that major LEA have worse clinical consequences: historically major LEA have been associated with lower functional status[48] and higher mortality rates compared to minor amputations[49]. Also, we should consider that patients undergoing minor LEA -including partial foot amputation- still do have a high risk of subsequent major LEA in their future[49]. Reduction of major LEA incidence on a regional level may therefore be regarded as a reflection of the effectiveness of health care services[50], with the reduction in the number of patients with PAD and/or DM undergoing a major LEA for the first time as the clinical outcome. However, a plateau of decreasing amputation rates may be reached in the future due to the relative increase in person-years of exposure to risk factors and the inevitability of amputation in some patients with advancing courses of PAD and DM.

**Conclusion**

Age-standardized incidence rate of first ever dysvascular major LEA in 2012–2013 was 7.7 per 100,000 person-years. Amputation rates were more than twice as high among men compared to women. Although age distribution in the Dutch population shifted considerably toward more elderly people, major LEA rates for persons aged >63 years decreased in 2012–2013 compared to the 1991–1992 cohort. Crude incidence rate of major LEA for the DM population decreased from 142.6 per 100,000 person-years in 2003–2004 to 89.2 per 100,000 person-years in 2012–2013, in which the amputation rates for DM patients aged ≥45 years were more than 8 times higher compared to the non-DM population.

**Supporting information**

S1 Table. Details of search strategy and inclusion/exclusion criteria. (DOCX)

S2 Table. Details and formulae illustrating calculations of age standardized incidence rates, confidence intervals and Poisson regression. (DOCX)

S3 Table. Crude incidence rates for DM and non-DM populations. (DOCX)

S4 Table. STROBE checklist. (DOC)

**Author Contributions**

**Conceptualization:** Behrouz Fard, Pieter U. Dijkstra, Jan H. B. Geertzen.

**Data curation:** Behrouz Fard.

**Formal analysis:** Behrouz Fard, Pieter U. Dijkstra, Roy E. Stewart, Jan H. B. Geertzen.

**Investigation:** Behrouz Fard.

**Methodology:** Behrouz Fard, Pieter U. Dijkstra, Roy E. Stewart.

**Project administration:** Behrouz Fard.

**Resources:** Jan H. B. Geertzen.

**Software:** Roy E. Stewart.

**Supervision:** Pieter U. Dijkstra, Roy E. Stewart, Jan H. B. Geertzen.
References

1. Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb disability: epidemiology and recent trends in the United States. South Med J. 2002; 95: 875–83. PMID: 12190225

2. GLEAS. Epidemiology of lower extremity amputation in centers in Europe, North America and East Asia. Br J Surg. 2000; 87: 328. https://doi.org/10.1046/j.1365-2168.2000.01344.x PMID: 10718803

3. Moxey PW, Gogalniceanu P, Hinchcliffe RJ, Loftus IM, Jones KJ, Thompson MM, et al. Lower extremity amputations—a review of global variability in incidence. Diabet Med. 2011; 28: 1144–53. https://doi.org/10.1111/diabmed.2011.03279.x PMID: 21384445

4. Narres M, Kvitkina T, Claessen H, Droste S, Schuster B, Morbach S, et al. Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: A systematic review. Grabowski A, editor. PLoS One. 2017; 12: e0182081. https://doi.org/10.1371/journal.pone.0182081 PMID: 28846690

5. Kroger K, Berg C, Santos A, Malvar M, Reinecke H. Lower Limb Amputation in Germany. Dtsch Arztebl Int. 2017; 114: 130–136. https://doi.org/10.3238/arztebl.2017.0130 PMID: 28302263

6. Rubio JA, Aragón-Sánchez J, Jiménez S, Guadalix G, Albarracín A, Salido C, et al. Reducing major lower extremity amputations after the introduction of a multidisciplinary team for the diabetic foot. Int J Low Extrem Wounds. 2014; 13: 22–6. https://doi.org/10.1177/1534734614521234 PMID: 24659624

7. Vamos EP, Bottle A, Majeed A, Millett C. Trends in lower extremity amputations in people with and without diabetes in England, 1996–2005. Diabetes Res Clin Pract. 2010; 87: 275–82. https://doi.org/10.1016/j.diabres.2009.11.016 PMID: 20021226

8. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- and nondiabetes-related lower extremity amputations before and after the introduction of better organized diabetes foot care: continuous longitudinal monitoring using a standard method. Diabetes Care. 2008; 31: 459–63. https://doi.org/10.2337/dc07-1159 PMID: 18071905

9. Lopez-de-Andres A, Jiménez-García R, Aragón-Sánchez J, Jiménez-Trujillo I, Hernández-Barrera V, Méndez-Bailón M, et al. National trends in incidence and outcomes in lower extremity amputations in people with and without diabetes in Spain, 2001–2012. Diabetes Res Clin Pract. 2015; 108: 499–507. https://doi.org/10.1016/j.diabres.2015.01.010 PMID: 25866357

10. Galván A, Violante MV, Mendes D, Moraes D, da Silva AM, de Almeida AJ, et al. Incidence of lower limb amputations in patients with diabetes mellitus and in patients without diabetes mellitus in the city of Belo Horizonte, Brazil. Rev Bras Endocrinol Metabol. 2013; 7: e20120006. https://doi.org/10.1590/1678-3610-2012-0006 PMID: 23952482

11. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- and nondiabetes-related lower extremity amputations before and after the introduction of better organized diabetes foot care: continuous longitudinal monitoring using a standard method. Diabetes Care. 2008; 31: 459–63. https://doi.org/10.2337/dc07-1159 PMID: 18071905

12. Almaraz MC, González-Romero S, Bravo M, Caballero FF, Palomo MJ, Vallejo R, et al. Incidence of lower limb amputations in individuals with and without diabetes mellitus in Andalusia (Spain) from 1998 to 2006. Diabetes Res Clin Pract. 2012; 95: 399–405. https://doi.org/10.1016/j.diabres.2011.10.035 PMID: 22133651

13. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007; 147: 417–22. PMID: 17876024

14. van Houtum WH, Rauwerda JA, Ruwaard D, Schaper NC, Bakker K. Reduction in diabetes-related lower-extremity amputations in The Netherlands: 1991–2000. Diabetes Care. 2004; 27: 1042–6. PMID: 15111518

15. Rogers RH, Laird JR. Overview of New Technologies for Lower Extremity Revascularization. Circulation. 2007; 116: 2072–2085. https://doi.org/10.1161/CIRCULATIONAHA.107.154333 PMID: 17967988

16. Tendera M, Aboyans V, Baumgartner I, Clement D, Collet J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease
of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2851–2906. https://doi.org/10.1093/eurheartj/ehr211 PMID: 21873417

18. Goodney PP, Tarulli M, Faerber AE, Schanzer A, Zwolak RM. Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among medicare patients. JAMA Surg. 2015; 150: 84–6. https://doi.org/10.1001/jamasurg.2014.1007 PMID: 25409197

19. World Health Organization. WHO Life expectancy. Geneva, 2016.

20. Fortington LV, Rommers GM, Postema K, van Netten JJ, Geertzen JHB, Dijkstra PU. Lower limb amputation in Northern Netherlands: unchanged incidence from 1991–1992 to 2003–2004. Prosthet Orthot Int. 2013; 37: 305–10. https://doi.org/10.1177/0309346412469385 PMID: 23327835

21. Rommers GM, Vos LD, Groothoff JW, Schuling CH, Eisma WH. Epidemiology of lower limb amputees in the north of The Netherlands: aetiology, discharge destination and prosthetic use. Prosthet Orthot Int. 1997; 21: 92–9. https://doi.org/10.3109/0309349709164536 PMID: 9285952

22. International Standardization Organization. ISO 8549–2: 1989—Prosthetics and orthotics—Vocabulary —Part 2: Terms relating to external limb prostheses and wearers of these prostheses [Internet]. 1989 [cited 25 Sep 2017] p. 2. Available: https://www.iso.org/standard/15801.html

23. Central Bureau for Statistics. StatLine [Internet]. [cited 25 Sep 2017]. Available: https://www.cbs.nl/en-gb/figures

24. Begg CB. Statistical methods in medical research P. Armitage and G. Berry, Blackwell Scientific Publications, Oxford, U.K., 1987. No. of pages: 559. Price £22.50. Stat Med. Wiley Subscription Services, Inc., A Wiley Company; 1988;7: 817–818. https://doi.org/10.1002/sim.4780070711

25. Boyle P, Parkin DM. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ. 1991; 126–58. PMID: 1894318

26. Ali A, Rasheed A, Siddiqui AA, Naseer M, Wasim S, Akhtar W. International Journal of Statistics in Medical Research. Lifescience Global; 2015. https://doi.org/10.6000/1929-6029.2015.04.03.7

27. Mackenbach JP, Slobbe L, Looman CWN, van der Heide A, Polder J, Garssen J. Sharp upturn of life expectancy in the Netherlands: effect of more health care for the elderly? Eur J Epidemiol. 2011; 26: 903–914. https://doi.org/10.1007/s10654-011-9633-y PMID: 22172945

28. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet (London, England). 2013; 382: 1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0

29. Overbeek JA, van der Heijden AWA, Herings RMC, Nijpels G. Proceedings of the National Diabetes Audit 2009-2011: Part 1: General Practitioners and General Practices. Diabetologia. 2013; 56: 1551-5. https://doi.org/10.1007/s00125-013-3030-z

30. Overbeek JA, van der Heijden AWA, Herings RMC, Nijpels G. Proceedings of the National Diabetes Audit 2009-2011: Part 2: Hospitals and General Practices. Diabetologia. 2013; 56: 1551-5. https://doi.org/10.1007/s00125-013-3030-z

31. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Fiedrichs S, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012; 28 Suppl 1: 125–139. https://doi.org/10.1002/dmrr.2249 PMID: 22271740

32. Voncina D, Bongaerts BWC, Müssig K, Wens J, Lang C, Schwarz P, Roden M, et al. Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. BMJ Open. 2017; 7: e013076. https://doi.org/10.1136/bmjopen-2016-013076 PMID: 28320788

33. Rubio JA, Aragón-Sánchez J, Jiménez S, Guadalix G, Albarracín A, Salido C, et al. Reducing Major Lower Extremity Amputations After the Introduction of a Multidisciplinary Team for the Diabetic Foot. Int J Low Extrem Wounds. 2014; 13: 22–26. https://doi.org/10.1177/15347346134652134 PMID: 24659624

34. Hinchcliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Friede S, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012; 28 Suppl 1: 179–217. https://doi.org/10.1002/dmrr.2249 PMID: 22271740

35. Bongaerts BWC, Müssig K, Wens J, Lang C, Schwarz J, Roden J, et al. Advanced leg salvage of the critically ischemic leg with major tissue loss by vascular and plastic surgeon teamwork: Long-term outcome. Ann Surg. 2006; 244: 949–57; discussion 957–8. https://doi.org/10.1097/01.sla.0000247985.45541.e8 PMID: 17122620

36. Dillon MP, Fortington LV, Akram M, Erbas B, Kohler F. Geographic Variation of the Incidence Rate of Lower Limb Amputation in Australia from 2007–2012. Nishimura W, editor. PLoS One. 2017; 12: e0170705. https://doi.org/10.1371/journal.pone.0170705 PMID: 28118408

37. Vamos EP, Bottle A, Edmonds ME, Valabhj V, Majeed A, Millett C. Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008. Diabetes Care. 2010; https://doi.org/10.2337/dc10-0462 PMID: 20807872
37. Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996–2005. J Vasc Surg. 2009; 49: 910–7. https://doi.org/10.1016/j.jvs.2008.11.054 PMID: 19341885

38. Dillon MP, Kohler F, Peeva V. Incidence of lower limb amputation in Australian hospitals from 2000 to 2010. Prosthet Orthot Int. 2014; 38: 122–32. https://doi.org/10.1177/0309364613490441 PMID: 23798042

39. Kennon B, Leese GP, Cochrane L, Colhoun H, Wild S, Stang D, et al. Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study. Diabetes Care. 2012; 35: 2586–90. https://doi.org/10.2337/dc12-0511 PMID: 23011727

40. Jørgensen ME, Almdal TP, Faerch K. Reduced incidence of lower-extremity amputations in a Danish diabetes population from 2000 to 2011. Diabet Med. 2014; 31: 443–7. https://doi.org/10.1111/dme.12320 PMID: 24111834

41. Kleefstra N, Landman GWD, Van Hateren KJJ, Meulepas M, Romeijnders A, Rutten GEH, et al. Dutch diabetes prevalence estimates (DUDE-1). J Diabetes. 2016; 8: 863–865. https://doi.org/10.1111/1753-0407.12370 PMID: 26694523

42. Fortington LV, Geerzten JHB, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013; 46: 124–31. https://doi.org/10.1016/j.ejvs.2013.03.024 PMID: 23628328

43. Dillingham TR, Pezzin LE, Shore AD. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil. 2005; 86: 480–6. https://doi.org/10.1016/j.apmr.2004.06.072 PMID: 15759232

44. Wiessman MP, Liberty IF, Segev RW, Katz T, Abu Tailakh M, Novack V. Clinical characteristics and survival of patients with diabetes mellitus following non-traumatic lower extremity amputation. Isr Med Assoc J. 2015; 17: 145–9. PMID: 25946764

45. Hawkins AT, Henry AJ, Crandell DM, Nguyen LL. A Systematic Review of Functional and Quality of Life Assessment after Major Lower Extremity Amputation. Ann Vasc Surg. 2014; 28: 763–780. https://doi.org/10.1016/j.avsg.2013.07.011 PMID: 24495325

46. Gallagher P, O’Donovan M-A, Doyle A, Desmond D. Environmental barriers, activity limitations and participation restrictions experienced by people with major limb amputation. Prosthet Orthot Int. 2011; 35: 278–84. https://doi.org/10.1016/j.jpros.2011.05.005 PMID: 21937573

47. Czerniecki JM, Turner AP, Williams RM, Hakimi KN, Norvell DC. Mobility changes in individuals with dysvascular amputation from the presurgical period to 12 months postamputation. Arch Phys Med Rehabil. 2012; 93: 1766–73. https://doi.org/10.1016/j.apmr.2012.04.011 PMID: 22543258

48. Peters EJ, Childs MR, Wunderlich RP, Harkless LB, Armstrong DG, Lavery LA. Functional status of persons with diabetes-related lower-extremity amputations. Diabetes Care. 2001; 24: 1799–804. PMID: 11574445

49. Dillingham TR, Pezzin LE, Shore AD. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil. 2005; 86: 480–486. https://doi.org/10.1016/j.apmr.2004.06.072 PMID: 15759232

50. Jeffercoate WJ, van Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia. 2004; 47: 2051–2058. https://doi.org/10.1007/s00125-004-1584-3 PMID: 15662547